Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Lewis LA, Vu DM, Granoff DM, Ram S.

Infect Immun. 2014 Jun;82(6):2574-84. doi: 10.1128/IAI.01517-14. Epub 2014 Mar 31.

2.

Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

van de Waterbeemd B, Zomer G, Kaaijk P, Ruiterkamp N, Wijffels RH, van den Dobbelsteen GP, van der Pol LA.

PLoS One. 2013 May 31;8(5):e65157. doi: 10.1371/journal.pone.0065157. Print 2013.

3.

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.

4.
5.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

6.

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM.

Vaccine. 2011 Jun 24;29(29-30):4728-34. doi: 10.1016/j.vaccine.2011.04.095. Epub 2011 May 13.

7.

Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins.

Ray TD, Lewis LA, Gulati S, Rice PA, Ram S.

J Immunol. 2011 Apr 15;186(8):4881-94. doi: 10.4049/jimmunol.1003623. Epub 2011 Mar 14.

8.
9.

Vaccine development against Neisseria meningitidis.

Vogel U, Claus H.

Microb Biotechnol. 2011 Jan;4(1):20-31. doi: 10.1111/j.1751-7915.2010.00178.x. Review.

10.

The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.

Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S.

PLoS Pathog. 2010 Jul 29;6(7):e1001027. doi: 10.1371/journal.ppat.1001027.

11.

Review of meningococcal group B vaccines.

Granoff DM.

Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S54-65. doi: 10.1086/648966. Review.

12.

Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter.

Oriente F, Scarlato V, Delany I.

J Bacteriol. 2010 Feb;192(3):691-701. doi: 10.1128/JB.01308-09. Epub 2009 Nov 30.

13.

Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Granoff DM.

Vaccine. 2009 Jun 24;27 Suppl 2:B117-25. doi: 10.1016/j.vaccine.2009.04.066. Epub 2009 May 23. Review.

14.

Factor H and neisserial pathogenesis.

Welsch JA, Ram S.

Vaccine. 2008 Dec 30;26 Suppl 8:I40-5. Review.

15.

Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Plested JS, Welsch JA, Granoff DM.

Clin Vaccine Immunol. 2009 Jun;16(6):785-91. doi: 10.1128/CVI.00007-09. Epub 2009 Apr 1.

16.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM.

J Infect Dis. 2009 May 1;199(9):1360-8. doi: 10.1086/597806.

17.

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Weynants V, Denoƫl P, Devos N, Janssens D, Feron C, Goraj K, Momin P, Monnom D, Tans C, Vandercammen A, Wauters F, Poolman JT.

Infect Immun. 2009 May;77(5):2084-93. doi: 10.1128/IAI.01108-08. Epub 2009 Mar 16.

19.

Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Koeberling O, Giuntini S, Seubert A, Granoff DM.

Clin Vaccine Immunol. 2009 Feb;16(2):156-62. doi: 10.1128/CVI.00403-08. Epub 2008 Dec 24.

20.

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Granoff DM, Welsch JA, Ram S.

Infect Immun. 2009 Feb;77(2):764-9. doi: 10.1128/IAI.01191-08. Epub 2008 Dec 1.

Items per page

Supplemental Content

Write to the Help Desk